Michele Senni1, Antonello Gavazzi1, Fabrizio Oliva2, Andrea Mortara3, Renato Urso4, Massimo Pozzoli5, Marco Metra6, Donata Lucci4, Lucio Gonzini4, Vincenzo Cirrincione7, Laura Montagna8, Andrea Di Lenarda9, Aldo P Maggioni10, Luigi Tavazzi5. 1. Cardiovascular Department, Ospedale Papa Giovanni XXIII, Bergamo, Italy. 2. Cardiologia 2 Heart Failure and Heart Transplant Program, "A. De Gasperis" Cardiovascular Dept., Niguarda Hospital, Milano, Italy. 3. Dept. of Clinical Cardiology and Heart Failure, Policlinico di Monza, Monza, Italy. 4. ANMCO Research Center, Firenze, Italy. 5. Maria Cecilia Hospital - GVM Care & Research - E.S. Health Science Foundation, Cotignola, Italy. 6. Cardiology, University and Spedali Civili, Brescia, Italy. 7. Cardiology-ICU Dept., AOR Villa Sofia-Cervello PO Villa Sofia, Palermo, Italy. 8. Cardiology Dept., Ospedale San Luigi Gonzaga, Orbassano, Italy. 9. Cardiovascular Unit, Azienda Servizi Sanitari n. 1 Triestina, Trieste, Italy. 10. ANMCO Research Center, Firenze, Italy. Electronic address: centrostudi@anmco.it.
Abstract
BACKGROUND: To investigate the outcomes of hospitalized patients with both de-novo and worsening heart failure (HF) with preserved left ventricular ejection fraction (LVEF) (HFpEF) (LVEF ≥ 50%), compared to those with reduced LVEF (HFrEF). METHODS AND RESULTS: We studied 1669 patients (22.6% HFpEF) hospitalized for acute HF in the prospective multi-center nationwide Italian Network on Heart Failure (IN-HF) Outcome Registry. In all patients LVEF was assessed during hospitalization. De-novo HF presentations constituted 49.6% of HFpEF and 43.1% of HFrEF hospitalizations. All-cause mortality during hospitalization was lower in HFpEF than HFrEF (2.9% vs 6.5%, p=0.01), but this mortality difference was not significant at 1 year (19.6% vs 24.4%, p=0.06), even after adjusting for clinical covariates. Similarly, there were no differences in 1-year mortality between HFpEF and HFrEF when compared by cause of death (cardiovascular vs non-cardiovascular) or mode of presentation (worsening HF vs de novo). Rehospitalization rates (all-cause, non-cardiovascular, cardiovascular, HF-related) at 90 days and 1 year were also similar. Mode of presentation influenced rehospitalizations in HFpEF, where those presenting with worsening HFpEF had higher all-cause (36.8% vs 21.6%, p=0.001), cardiovascular (28.1% vs 14.9%, p=0.002), and HF-related (21.1% vs 7.7%, p=0.0003) rehospitalization rates at 1 year compared to those with de novo presentations. CONCLUSIONS: Outcomes at 1 year following hospitalization for HFpEF are as poor as that of HFrEF. A prior history of HF decompensation or hospitalization identifies patients with HFpEF at particularly high risk of recurrent events. These findings may have implications for clinical practice, quality and process improvements and trial design.
BACKGROUND: To investigate the outcomes of hospitalized patients with both de-novo and worsening heart failure (HF) with preserved left ventricular ejection fraction (LVEF) (HFpEF) (LVEF ≥ 50%), compared to those with reduced LVEF (HFrEF). METHODS AND RESULTS: We studied 1669 patients (22.6% HFpEF) hospitalized for acute HF in the prospective multi-center nationwide Italian Network on Heart Failure (IN-HF) Outcome Registry. In all patients LVEF was assessed during hospitalization. De-novo HF presentations constituted 49.6% of HFpEF and 43.1% of HFrEF hospitalizations. All-cause mortality during hospitalization was lower in HFpEF than HFrEF (2.9% vs 6.5%, p=0.01), but this mortality difference was not significant at 1 year (19.6% vs 24.4%, p=0.06), even after adjusting for clinical covariates. Similarly, there were no differences in 1-year mortality between HFpEF and HFrEF when compared by cause of death (cardiovascular vs non-cardiovascular) or mode of presentation (worsening HF vs de novo). Rehospitalization rates (all-cause, non-cardiovascular, cardiovascular, HF-related) at 90 days and 1 year were also similar. Mode of presentation influenced rehospitalizations in HFpEF, where those presenting with worsening HFpEF had higher all-cause (36.8% vs 21.6%, p=0.001), cardiovascular (28.1% vs 14.9%, p=0.002), and HF-related (21.1% vs 7.7%, p=0.0003) rehospitalization rates at 1 year compared to those with de novo presentations. CONCLUSIONS: Outcomes at 1 year following hospitalization for HFpEF are as poor as that of HFrEF. A prior history of HF decompensation or hospitalization identifies patients with HFpEF at particularly high risk of recurrent events. These findings may have implications for clinical practice, quality and process improvements and trial design.
Authors: Melissa C Caughey; Carla A Sueta; Sally C Stearns; Amil M Shah; Wayne D Rosamond; Patricia P Chang Journal: Am J Cardiol Date: 2018-03-28 Impact factor: 2.778
Authors: Susana Garcia-Gutierrez; José Maria Quintana; Ane Antón-Ladislao; Maria Soledad Gallardo; Esther Pulido; Irene Rilo; Elena Zubillaga; Miren Morillas; José Juan Onaindia; Nekane Murga; Ricardo Palenzuela; José González Ruiz Journal: Intern Emerg Med Date: 2016-10-11 Impact factor: 3.397
Authors: Michele Senni; Walter J Paulus; Antonello Gavazzi; Alan G Fraser; Javier Díez; Scott D Solomon; Otto A Smiseth; Marco Guazzi; Carolyn S P Lam; Aldo P Maggioni; Carsten Tschöpe; Marco Metra; Scott L Hummel; Frank Edelmann; Giuseppe Ambrosio; Andrew J Stewart Coats; Gerasimos S Filippatos; Mihai Gheorghiade; Stefan D Anker; Daniel Levy; Marc A Pfeffer; Wendy Gattis Stough; Burkert M Pieske Journal: Eur Heart J Date: 2014-08-07 Impact factor: 29.983